2. Search Result
Search Result
Results for "

glioma

" in MedChemExpress (MCE) Product Catalog:

175

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dye

4

Biochemical Assay Reagents

8

Peptides

1

MCE Kits

6

Inhibitory Antibodies

27

Natural
Products

7

Recombinant Proteins

12

Isotope-Labeled Compounds

3

Antibodies

1

Click Chemistry

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-117651
    2-Fluoropalmitic acid

    		Acyltransferase Cancer
    2-Fluoropalmitic acid, an acyl-CoA synthetase inhibitor, acts as a candidate anti-glioma agent. 2-Fluoropalmitic acid suppresses the viability and stem-like phenotype of glioma stem cells (GSCs). 2-Fluoropalmitic acid also inhibits proliferation and invasion of glioma cell lines .
    2-Fluoropalmitic acid
  • HY-B0896
    Triacetin

    Glyceryl triacetate; 1,2,3-Triacetoxypropane

    		 Apoptosis HDAC Cancer
    Triacetin (Glyceryl triacetate) is a synthetic compound that is a triester of glycerol and acetic acid, orally active. Triacetin increases acetate bioavailability in glioma cells. Triacetin induces glioma cell growth arrest and Apoptosis. Triacetin freely crosses the blood brain barrier/plasma membrane. Triacetin increases histone acetylation and enhances Temozolomide (HY-17364) (TMZ) chemotherapeutic efficacy .
    Triacetin
  • HY-B0754A
    Hematoporphyrin dihydrochloride
    10+ Cited Publications

    Hematoporphyrin IX dihydrochloride

    		 Apoptosis Endogenous Metabolite Cancer
    Hematoporphyrin dihydrochloride (Hematoporphyrin IX dihydrochloride), a photosensitizer, is a substrate for affinity chromatography of heme-binding proteins. Hematoporphyrin dihydrochloride can induce apoptosis in U87 glioma cells and decrease tumor growth in vivo when exposed to red light .
    Hematoporphyrin dihydrochloride
  • HY-P10983
    LS10

    		Biochemical Assay Reagents Cancer
    LS10 can specifically bind to NG2 protein and is a functional ligand for targeted drug delivery to glioma. NG2 proteins are widely overexpressed in the glioma cells and restricted in normal tissue .
    LS10
  • HY-123410
    KM-233

    		Cannabinoid Receptor Cancer
    KM-233 is a classical cannabinoid with good blood brain barrier penetration. KM-233 possesses a selective affinity for the CB2 receptors relative to THC. KM-233 is effective at reducing U87 glioma tumor burden, and can be used for glioma research .
    KM-233
  • HY-W102669
    Spiro[4.5]decane-7,9-dione

    		Drug Intermediate Cancer
    Spiro[4.5]decane-7,9-dione (Compound 2e) is a cyclic 1,3-diketone. Spiro[4.5]decane-7,9-dione can be used in the study of glioma tumors .
    Spiro[4.5]decane-7,9-dione
  • HY-137831
    TLBC

    		Apoptosis Cancer
    TLBC, a boronic-chalcone derivative, shows a dose-dependent inhibition with IC50 values of 5.5-25.5 μM in various glioma cell lines. TLBC induces apoptosis independent of changes to the tumor suppressor p53 .
    TLBC
  • HY-10587A
    BIX-01294 hydrochloride hydrate

    		Histone Methyltransferase Apoptosis Autophagy Cancer
    BIX-01294 hydrochloride hydrate is a histone-lysine methyltransferase (HMTase) inhibitor, which selective inhibits the G9aHMTase with IC50 of 1.7 μM, reduces histone-3 lysine (9) methylation (H3K9me), induces autophagy and apoptosis in human glioma cells .
    BIX-01294 hydrochloride hydrate
  • HY-P99772
    Onfekafusp alfa

    L19TNF

    		 TNF Receptor Cancer
    Onfekafusp alfa (L19TNF) is a homotrimer that forms from engineered peptides for the L19 antibody in scFv format fused to human TNF. Onfekafusp alfa can be used for malignant glioma research .
    Onfekafusp alfa
  • HY-N11108
    Gochnatiolide A

    		Others Cancer
    Gochnatiolide A is a dimeric sesquiterpene that can be found in Ainsliaea henryi. Gochnatiolide A exhibits antiproliferative activity against the kidney, melanoma, ovarian-resistant and glioma cell lines .
    Gochnatiolide A
  • HY-B0754
    Hematoporphyrin

    Hematoporphyrin IX

    		 Apoptosis Endogenous Metabolite Cancer
    Hematoporphyrin (Hematoporphyrin IX), a photosensitizer, is a substrate for affinity chromatography of heme-binding proteins. Hematoporphyrin can induce apoptosis in U87 glioma cells and decrease tumor growth in vivo when exposed to red light .
    Hematoporphyrin
  • HY-171468
    CC-1069

    		TNF Receptor Cancer
    CC-1069, a structural analog of thalidomide (HY-14658), is a TNF-α inhibitor that inhibits endothelial. CC-1069 can be used to study angiogenesis-dependent tumors such as gliomas .
    CC-1069
  • HY-157422
    CSF1R-IN-19

    		c-Fms Cancer
    CSF1R-IN-19 is a potent inhibitor of CSF1R. CSF1R-IN-19 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-19 has the potential for the research of cancer .
    CSF1R-IN-19
  • HY-113763
    TWEAK-Fn14-IN-1

    		TNF Receptor Others
    TWEAK-Fn14-IN-1 (Compound L524-0366) is a specific dose-dependent TWEAK-Fn14 inhibitor. TWEAK-Fn14-IN-1 binds specifically to the Fn14 surface with a KD of 7.12 μM. TWEAK-Fn14-IN-1 inhibits TWEAK induced glioma cell migration without any potential cytotoxic effects .
    TWEAK-Fn14-IN-1
  • HY-100355R
    C18-Ceramide (Standard)

    		Endogenous Metabolite Reference Standards Neurological Disease Cancer
    C18-Ceramide (Standard) is the analytical standard of C18-Ceramide. This product is intended for research and analytical applications. C18-Ceramide can promote exocytosis of glutamate from damaged neurons. C18-Ceramide promotes cell death in glioma cells. Ceramides is involved in diverse cellular functions, such as differentiation, cell cycle progression, cell-cell adhesion, senescence, and apoptosis .
    C18-Ceramide (Standard)
  • HY-167864
    M4K2308

    		TGF-β Receptor Cancer
    M4K2308 is a selective ether-linked inhibitor of ALK2 with an IC50 of 2 nM. M4K2308 exhibits exceptional selectivity for ALK2 over ALK5 (IC50 of 224 nM). M4K2308 has the potential for the study of diffuse intrinsic pontine glioma (DIPG) research .
    M4K2308
  • HY-121736
    AGI-12026

    AGI-026

    		 Isocitrate Dehydrogenase (IDH) Neurological Disease
    AGI-12026 is brain-penetrant dual inhibitor of mutant IDH1 and 2. AGI-12026 shows partial inhibition of the IDH1-R132H homodimer as allosteric modulators. AGI-12026 has the potential for research of glioma .
    AGI-12026
  • HY-10293
    Aderbasib

    INCB007839; INCB7839

    		 MMP Cancer
    Aderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large B-cell non-Hodgkin lymphoma, HER2 + breast cancer, gliomas, et al .
    Aderbasib
  • HY-129079
    TFMB-(R)-2-HG
    1 Publications Verification

    		 Estrogen Receptor/ERR Histone Demethylase Fat Mass and Obesity-associated Protein (FTO) Cancer
    TFMB-(R)-2-HG is a cell membrane-permeable (R)-2-HG and acute myeloid leukemia (AML) oncogenic factor. TFMB-(R)-2-HG competitively inhibits α-ketoglutarate-dependent dioxygenases such as KDM2B and FTO. TFMB-(R)-2-HG impairs cell differentiation in response to Estrogen withdrawal. TFMB-(R)-2-HG is used in acute myeloid leukemia and glioma research .
    TFMB-(R)-2-HG
  • HY-142706
    MAO A/HDAC-IN-1

    		Monoamine Oxidase HDAC Cancer
    MAO A/HDAC-IN-1 is a dual?inhibitor?of monoamine oxidase A (MAO A) and HDAC. MAO A/HDAC-IN-1 can be used for glioma research . MAO A/HDAC-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    MAO A/HDAC-IN-1
  • HY-W023758
    HDGFRP2/PSIP1-IN-1

    4-(4-Bromo-1H-pyrazol-5-yl)pyridine

    		 DNA/RNA Synthesis Cancer
    HDGFRP2/PSIP1-IN-1 (compound BPP) is a dual inhibitor targeting the PWWP domain of hepatocarcinogenic growth factor-related protein 2 (HDGFRP2) and its homologous protein PSIP1, hinder the development and progression of diffuse intrinsic pontine glioma (DIPG). HDGFRP2/PSIP1-IN-1 binds to HDGFRP2 with a Kd value of 7 μM and a ligand efficiency of 0.47; it binds to the PSIP1 PWWP domain with a Kd value of 27 μM; meanwhile, it has a Kd value of 14 μM for HDGFRP3, indicating its effectiveness as an inhibitor of the HDGFRP2 PWWP subfamily .
    HDGFRP2/PSIP1-IN-1
  • HY-176508
    KDX1381

    		Casein Kinase Cancer
    KDX1381 is a bivalent CK2α inhibitor (IC50: 17 nM, KD: 54 nM). KDX1381 has antitumor activity in mouse 786-O and A375 tumor xenograft models. KDX1381 combined with VEGFR inhibitors or DNA damaging agents enhances antitumor efficacy in mouse hepatocellular carcinoma and glioma models .
    KDX1381
  • HY-117903A
    MRT-92

    		Smo Hedgehog Cancer
    MRT-92 is a Smoothened (Smo) antagonist (Ki=0.7 nM) with anticancer activity. MRT-92 inhibits Hedgehog signaling pathway and rodent cerebellar granule cell proliferation by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor (IC50=0.4 nM). MRT-92 can be used in the study of cerebellar glioma .
    MRT-92
  • HY-115452
    G5-7

    		JAK Apoptosis Cancer
    G5-7, an orally active and allosteric JAK2 inhibitor, selectively inhibits JAK2 mediated phosphorylation and activation of EGFR (Tyr 1068) and STAT3 by binding to JAK2. G5-7 induces cell cycle arrest, apoptosis and possesses antiangiogenic effect. G5-7 has the potential for glioma study .
    G5-7
  • HY-10521
    Darapladib
    5+ Cited Publications

    SB-480848

    		 Phospholipase Apoptosis Cardiovascular Disease Cancer
    Darapladib (SB-480848) is an orally active, selective and reversible Lp-PLA2 inhibitor (IC50=0.25 nM). Darapladib can trigger irreversible actions on glioma cell apoptosis and induce cycle arrest. Darapladib can be used in the study of atherosclerosis and cancer .
    Darapladib
  • HY-144041
    CSF1R-IN-5

    		c-Fms Cancer
    CSF1R-IN-5 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-5 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-5 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 11) .
    CSF1R-IN-5
  • HY-144040
    CSF1R-IN-4

    		c-Fms Cancer
    CSF1R-IN-4 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-4 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-4 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 104) .
    CSF1R-IN-4
  • HY-144042
    CSF1R-IN-6

    		c-Fms Cancer
    CSF1R-IN-6 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-6 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-6 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 5) .
    CSF1R-IN-6
  • HY-100355
    C18-Ceramide

    		Endogenous Metabolite Neurological Disease Cancer
    C18-Ceramide is a bioactive molecule with multiple functions in cells, can cross the blood-brain barrier, not a traditional agonist or inhibitor targeting a single site. It can act on multiple cellular targets, such as proteins related to endoplasmic reticulum stress (e.g., ATF-4, XBP-1, CHOP), proteins in the PI3K/AKT signaling pathway, and SNARE complex proteins. It exerts activities like inducing cell death, promoting autophagy, and regulating exocytosis through mechanisms such as activating endoplasmic reticulum stress, inhibiting the PI3K/AKT signaling pathway, and affecting lipid raft - related functions. It can be used in research on the mechanism of neuronal injury in the field of neuroscience and in the treatment research of cancers such as glioma in the field of oncology .
    C18-Ceramide
  • HY-139604
    PCC0208017
    2 Publications Verification

    		 MARK Apoptosis Cancer
    PCC0208017 is a microtubule affinity regulating kinases (MARK3/MARK4) inhibitor with IC50s of 1.8 and 2.01 nM, respectively. PCC0208017 has much lower inhibitory activity against MARK1 and MARK2, with IC50s of 31.4 and 33.7 nM, respectively. PCC0208017 suppresses glioma progression in vitro and in vivo. PCC0208017 disrupts microtubule dynamics and induces G2/M phase cell cycle arrest and cell apoptosis. PCC0208017 demonstrates robust antitumor activity in vivo and displays good BBB permeability .
    PCC0208017
  • HY-173431
    Dopamine D4 receptor ligand 3

    		Dopamine Receptor Reactive Oxygen Species (ROS) Cancer
    Dopamine D4 receptor ligand 3 (Compound 16) is a dopamine D4 receptor (D4R) antagonist (pKi: 8.86). Dopamine D4 receptor ligand 3 has pIC50 values of 5.78, 5.55, and 6.17 for Go, Gi, and βArr2 sensors in HEK-293T cells, respectively. Dopamine D4 receptor ligand 3 inhibits the viability of three human glioma cell lines, U87 MG, T98G, and U251 MG. Dopamine D4 receptor ligand 3 induces ROS production and mitochondrial dysfunction in glioma cells .
    Dopamine D4 receptor ligand 3
  • HY-N7255
    Cycloartenol

    		p38 MAPK Apoptosis Cancer
    Cycloartenol, a phytosterol compound, is one of the key precusor substances for biosynthesis of numerous sterol compounds. Cycloartenol inhibits the migration of glioma cells and suppresses the phosphorylation of the p38 MAP kinase. Cycloartenol has a variety of pharmacological activities such as anti-inflammatory, anti-tumor, antioxidant, antibiosis and anti-alzheimer's disease. Cycloartenol also plays an important role in the process of plant growth and development .
    Cycloartenol
  • HY-146245C
    ODN 1826 sodium
    4 Publications Verification

    CpG 1826 sodium

    		 Toll-like Receptor (TLR) Apoptosis NO Synthase Cardiovascular Disease Inflammation/Immunology Cancer
    ODN 1826 sodium is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 sodium induces NO and iNOS production and enhances Apoptosis. ODN 1826 sodium enhances immune surveillance. ODN 1826 sodium increases aortic atherosclerotic plaque size. ODN 1826 sodium has antitumor activity against lung cancer, glioma and melanoma .
    ODN 1826 sodium
  • HY-144707
    AK-778-XXMU

    		Apoptosis Cancer
    AK-778-XXMU is a potent inhibitor of DNA Binding 2 (ID2) antagonist with a KD of 129 nM. AK-778-XXMU can inhibit cell migration and invasion of glioma cell lines, induce apoptosis, and more importantly, slow down the tumor growth .
    AK-778-XXMU
  • HY-149556
    MTX-241F

    		EGFR PI3K Cancer
    MTX-241F is a selective small molecule inhibitor targeting EGFR and PI3 kinase family members. MTX-241F is able to penetrate the blood-brain barrier and control tumor growth over the long term. MTX-241F exhibits radiosensitizing activity in patient-derived DIPG neurospheres and may be used in the study of diffuse intrinsic pontine glioma (DIPG) .
    MTX-241F
  • HY-158251
    BIBD-300

    		Others Cancer
    BIBD-300 is a PARP-1 imaging agent with high affinity for PARP-1. BIBD-300 can accurately localize C6 and U87MG tumors, which can be used for research in the diagnosis of breast cancer, prostate cancer, glioma, and liver cancer .
    BIBD-300
  • HY-10521R
    Darapladib (Standard)

    SB-480848 (Standard)

    		 Reference Standards Phospholipase Apoptosis Cardiovascular Disease Cancer
    Darapladib (Standard) is the analytical standard of Darapladib. This product is intended for research and analytical applications. Darapladib (SB-480848) is an orally active, selective and reversible Lp-PLA2 inhibitor (IC50=0.25 nM). Darapladib can trigger irreversible actions on glioma cell apoptosis and induce cycle arrest. Darapladib can be used in the study of atherosclerosis and cancer .
    Darapladib (Standard)
  • HY-N7255R
    Cycloartenol (Standard)

    		Reference Standards p38 MAPK Apoptosis Cancer
    Cycloartenol (Standard) is the analytical standard of Cycloartenol. This product is intended for research and analytical applications. Cycloartenol, a phytosterol compound, is one of the key precusor substances for biosynthesis of numerous sterol compounds. Cycloartenol inhibits the migration of glioma cells and suppresses the phosphorylation of the p38 MAP kinase. Cycloartenol has a variety of pharmacological activities such as anti-inflammatory, anti-tumor, antioxidant, antibiosis and anti-alzheimer's disease. Cycloartenol also plays an important role in the process of plant growth and development .
    Cycloartenol (Standard)
  • HY-142533
    HL-PEG2k

    		Biochemical Assay Reagents Cancer
    HL-PEG2k is a second near-infrared Ru(II) polypyridyl complex. HL-PEG2k exhibits a wavelength bathochromic shift, enhanced photothermal conversion efficiency (41.77%), and an antineoplastic effect against glioma. HL-PEG2k displays a superior biocompatibility and thus can be a potential theranostic platform to combat the growth and recurrence of tumors .
    HL-PEG2k
  • HY-147670
    TPB15

    		Hedgehog Smo Gli Apoptosis Cancer
    TPB15 is an orally active and potent Hh (Hedgehog) signaling inhibitor. TPB15 markedly induces cell cycle arrest and apoptosis in MDA-MB-468 cells. TPB15 blocks Smo (Smoothened) translocation into the cilia and reduced Smo protein and mRNA expression. TPB15 inhibits the expression of the downstream regulatory factor glioma-associated oncogene 1 (Gli1). TPB15 shows good anti-tumor activity with low toxicity .
    TPB15
  • HY-163290
    HDAC-MB

    		Fluorescent Dye Monoamine Oxidase Cancer
    HDAC-MB a probe that is activated by HDAC6 and can detect and eliminate glioma cells through activation by HDAC6. HDAC-MB reveals antimetastatic and antiproliferative properties, inhibits glioma invasion and induces cellular apoptosis .
    HDAC-MB
  • HY-121931
    AA863

    		Lipoxygenase Cancer
    AA863 is a 5-lipoxygenase inhibitor with activity in inhibiting the proliferation of human glioma cells. AA863 exhibits significant and dose-dependent inhibitory effects in monolayer cultured glioma cells with an IC50 of 9.0 micromolar .
    AA863
  • HY-139712
    PDGFP 1

    		Fluorescent Dye Others
    PDGFP 1 is a promising probe for simultaneously differentiating glioma boundary and grades.
    PDGFP 1
  • HY-174212
    MXC-017

    		Apoptosis Cancer
    MXC-017 is a BBB-penetrable apoptosis inducer, directly targeting glioma stem cells (GSCs). MXC-017 prevents radiation-induced GSC formation but increases G0/G1 arrest and apoptosis. MXC-017 has minimal off-target effects with no significant cell toxicity up to 10 µM. MXC-017 significantly extends median survival in patient-derived orthotopic xenograft (PDOX) glioblastoma (GBM) mice models with combination of radiation .
    MXC-017
  • HY-N15582
    Perezone

    		Apoptosis Inflammation/Immunology Cancer
    Perezone is a sesquiterpenoid benzoquinone found in the roots of Acourtia species. Perezone inhibits the activity of leukemia cell line K-562 and human glioma cell line U-251 (IC50: 6.83 μM). Perezone increases the expression of caspase 3, 8, and 9 genes associated with apoptosis. Perezone has antioxidant and anti-inflammatory activities .
    Perezone
  • HY-P9973
    Brolucizumab

    DLX1008; ESBA 1008; RTH258

    		 VEGFR Cancer
    Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (KD=1.05 pM). Brolucizumab can be used for the research of cancer .
    Brolucizumab
  • HY-N7844
    N6-Benzyladenosine

    Benzyladenosine

    		 Apoptosis Adenosine Receptor Inflammation/Immunology Cancer
    N6-Benzyladenosine is an adenosine receptor agonist, has a cytoactive activity. N6-Benzyladenosine arrests cell cycle at G0/G1 phase and induces cell apoptosis. N6-Benzyladenosine also exerts inhibitory effect on T. gondii adenosine kinase and glioma - .
    N6-Benzyladenosine
  • HY-16444
    Sagopilone

    ZK-EPO; ZK 219477

    		 Microtubule/Tubulin Cancer
    Sagopilone (ZK-EPO) demonstrated antitumor activity in human orthotopic glioma models both in vitro and in vivo .
    Sagopilone
  • HY-P991419
    MSB-0254

    		VEGFR Cancer
    MSB-0254 is a human monoclonal antibody (mAb) targeting VEGFR2/KDR/CD309. MSB-0254 inhibits the invasion, migration, and vascular mimetic (VM) formation of U251 and primary glioma cells. MSB-0254 inhibits the growth of U251 and GL261 cell transplanted tumors. MSB-0254 reduces the expression of CD34, VEGFR2, Ki67, MMP2, MMP9, and CD34/PAS. MSB-0254 can be used in advanced solid tumors research .
    MSB-0254
  • HY-150082
    CP681301

    		CDK DNA/RNA Synthesis Cancer
    CP681301 is a potent CDK5 inhibitor. CP681301 shows antiproliferative activity. CP681301 decreases the expression of CD133, OLIG2, SOX2, KI67, pCDK5 protein level in GSCs (Glioma stem cells). CP681301 reduces self-renewal in mouse glioma xenografts. CP681301 shows anti-tumor activity in Drosophila .
    CP681301

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: